gastric protein comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-20. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
== Basics of extract preparation == The cell cycle of unfertilized eggs of X. laevis is arrested highly synchronously at metaphase of meiosis II. Upon fertilization, the metaphase arrest is released by the action of Ca2+ ions released from the endoplasmic reticulum, thereby initiating early embryonic cell cycles that alternates S phase (DNA replication) and M phase (mitosis).
=== Pseudohyperkalemia === Pseudohyperkalemia occurs when the measured potassium level is falsely elevated. Mechanical trauma during blood drawing can cause potassium leakage out of the red blood cells due to haemolysis of the blood sample. Fist clenching during the blood draw can cause a rise in potassium levels in the venous blood as it is sampled; this difference may be as much as 1 mmol/L. Differences of this order of magnitude cause problems (false positive results for clinically-important hyperkalemia) for patients with low glomerular filtration rate (GFR; a measure of kidney function), type IV renal tubular acidosis (RTA), or on evidence-based medication for cardio-renal risk (RASi, MRAs). The practice, widespread in laboratories in North America, should be discontinued. Prolonged storage of blood samples or agitation in transit is also associated with red cell lysis that can increase serum potassium levels. Hyperkalemia may become apparent when a person's platelet concentration is more than 500,000/microL in a clotted blood sample (serum blood sample). Potassium leaks out of platelets after clotting has occurred. A high white cell count (greater than 120,000/microL) in people with chronic lymphocytic leukemia increases the fragility of red blood cells, thus causing pseudohyperkalemia during blood processing. This problem can be avoided by processing serum samples, because clot formation protects the cells from haemolysis during processing.
== As a drug target == Xenin promotes beta-cell survival and xenin has been evaluated in animal models of obesity and diabetes where it has demonstrated an antidiabetic potential. In humans, co-administration of xenin-25 and gastric inhibitory polypeptide (GIP) reduces postprandial glycemia by delaying gastric emptying.
Self-assembly is a scalable and parallel process which can involve large numbers of components in a short timeframe. Can result in structural dimensions across orders of magnitude, from nanoscale to macroscale. Is relatively inexpensive compared to the top-down assembly approach, which often consumes large amounts of finite resources. Natural processes that drive self-assembly tend to be highly reproducible. The existence of life is strongly dependent on the reproducibility of self-assembly. Challenges There exist several outstanding challenges in self-assembly, due to a variety of competing factors. Currently self-assembly is difficult to control on large scales, and to be widely applied we will need to ensure high degrees of reproducibility at these scales. The fundamental thermodynamic and kinetic mechanisms of self-assembly are poorly understood - the basic principles of atomistic and macroscale processes can be significantly different than those for nanostructures. Concepts related to thermal motion and capillary action influence equilibrium timescales and kinetic rates that are not well defined in self-assembling systems. Top-down vs bottom-up synthesis
Sources: en.wikipedia.org
initiation factor (IF) Any of various proteins which bind to the small or large subunit of ribosomes during the initiation of translation and thereby play roles in regulating when and how protein synthesis occurs. Initiation factors are essential for assembly of the initiation complex and for charged transfer RNAs to properly associate with the ribosome and the messenger RNA. They are frequent targets of activators and repressors which can respectively increase or decrease the rate of translation. Though their functions are largely conserved, they are distinguished by the taxonomic domain in which they occur: bacterial initiation factors (IFs), archaeal initiation factors (aIFs), and eukaryotic initiation factors (eIFs).
However, Ben Kiernan and Taylor Owen suggest that "the bombs drove ordinary Cambodians into the arms of the Khmer Rouge, a group that seemed initially to have slim prospects of revolutionary success." Kissinger himself defers to others on the subject of casualty estimates: "...since I am in no position to make an accurate estimate of my own, I consulted the OSD Historian, who gave me an estimate of 50,000 based on the tonnage of bombs delivered over the period of four and a half years." A number of Republican politicians complained to Nixon that his stance on Vietnam was hurting their chances for congressional elections in November 1970, leading the president to say to Kissinger it was natural that liberals like Senator George McGovern and Senator Mark Hatfield wanted to "bug out...But when the Right starts wanting to get out, for whatever reason, that's our problem". In an attempt to change Nixon's image, Kissinger and Nixon devised the notion of a "standstill cease-fire," where both sides would occupy whatever areas of South Vietnam they were holding at the time of the ceasefire, an offer that Nixon publicly made in a television address on 7 October 1970. In his speech, Nixon apparently moved away from the "mutual withdrawal formula" the North Vietnamese kept rejecting by not mentioning it, winning much acclaim, even from his opponents like McGovern and Hatfield (though he also said the withdrawal of U.S. forces would be "based on principles" he had "previously" discussed, i.e. the "mutual withdrawal formula").
== Role of microchimerism in wound healing == Microchimeric fetal cells expressed collagen I, III and TGF-β3, and they were identified in healed maternal cesarean section scars. This suggests that these cells migrate to the site of damage due to maternal skin injury signals, and help repair tissue.
== History == Elagolix was first described in the literature in 2005. It was originally developed by the pharmaceutical company Neurocrine Biosciences, and was later developed together by Neurocrine Biosciences and AbbVie (previously Abbott Laboratories). In June 2010, Neurocrine Biosciences and Abbott announced a global agreement to develop and commercialize elagolix for the treatment of endometriosis. The medication completed phase III clinical trials for endometriosis in November 2016. Two phase III clinical trials, the Elaris Endometriosis I and II (EM-I and EM-II) studies, were conducted. The studies included almost 1,700 women, about 950 of whom were treated with elagolix. In September 2017, AbbVie filed a New Drug Application (NDA) for elagolix for the treatment of pain associated with endometriosis in the United States. The medication was approved by the FDA for the treatment of endometriosis-associated pain in the United States on 23 July 2018. It was the first new medication to be approved by the FDA for the treatment of endometriosis in more than a decade. Elagolix was the first member of a new class of GnRH modulators described as "second-generation" due to their non-peptide and small-molecule nature and oral activity to be marketed. A second member of this group, relugolix (brand name Relumina), was introduced in Japan in January 2019. In addition to endometriosis, elagolix is under development for the treatment of uterine fibroids and menorrhagia. It is in phase III clinical trials for these indications.
=== July === 1 July – Local Government Minister Lee Rowley formally writes to South Cambridgeshire District Council to request they end their trial of a four-day working week "immediately" amid concerns about "value for money". The scheme, launched in January 2023, is scheduled to run until March 2024. Seven Just Stop Oil protestors are arrested after attempting to disrupt the 2023 London Pride celebrations by blocking the route of the parade. Five people are subsequently charged in connection with the incident. 2 July – Amanda Pritchard, the Chief Executive of NHS England, announces the launch of a further seven specialist gambling addiction clinics in England as the number of people being referred for help because of gambling addiction sees a sharp increase. 3 July – Lord Chancellor and Justice Secretary Alex Chalk asks the Parole Board to reconsider its decision to release child killer Colin Pitchfork. Ranibizumab, a drug that can prevent blindness in premature babies, is made available on the NHS in England. 4 July – Thames Water is fined £3.3m for discharging millions of litres of untreated sewage into two rivers which resulted in the death of 1,400 fish. Forest Green Rovers appoint Hannah Dingley as their caretaker manager, making her the first woman to manage a men's football team in English professional football. 5 July – Train companies in England launch a 21-day consultation over plans to closing hundreds of ticket offices. Two Just Stop Oil protestors briefly halt play at the 2023 Wimbledon Championships by invading the tennis court and throwing orange confetti.
Sources: en.wikipedia.org
Selectivity of a cyclodextrin phase is dependent on two key factors namely the size and structure of the analyte since it is based on a simple fit-unfit geometric criteria. An aromatic ring or cycloalkyl ring should be attached near the stereogenic center of the analyte. Substituents at or near the analyte chiral center must be able to interact with the hydroxyl groups at the entrance of the CD cavity through H-bonding. α-Cyclodextrin holds small aromatic molecules, whereas β-cyclodextrin incorporates both naphthyl groups and substituted phenyl groups. The aqueous compatibility of CD and its unique molecular structure make the CD- bonded phase highly suitable for use in chiral HPLC analysis of drugs. One further benefit of CD is that they are generally less expensive than the other CSPs. Some of the major shortcomings of CD CSPs is that it is limited to compounds that can enter into CD cavity, minor structural changes in analyte leads to unpredictable effect on resolution, often poor efficiency and cannot invert elution order.
The ICRU and ICRP specify differently defined weighting factors that apply to environmental measurements (quality factor) and body-related dose equivalent data (radiation weighting factor). In relation to the body, the relevant dose term is the Organ Equivalent Dose (formerly "Organ Dose"). This is the dose equivalent averaged over an organ. Multiplied by organ-specific tissue weighting factors and summed over all organs, the effective dose is obtained, which represents a dose balance. In relation to environmental measurements, the ambient dose equivalent or local dose is relevant. Its increase over time is called the local dose rate. Even at very low effective doses, stochastic effects (genetic and cancer risk) are expected. At effective doses above 0.1 Sv, deterministic effects also occur (tissue damage up to radiation sickness at very high doses). Correspondingly high radiation doses are now only given in units of Gy. Natural radiation exposure in Germany, with an annual average effective dose of about 0.002 Sv, is well below this range.
A dehydroalanine residue was long thought to be an important electrophilic catalytic residue in histidine ammonia-lyase and phenylalanine ammonia-lyase enzymes, but the active residue was later found instead to be a different unsaturated alanine derivative — 3,5-dihydro-5-methyldiene-4H-imidazol-4-one — that is even more electrophilic.
==== Early life stress ==== Epigenetic modifications including DNA methylation and histone acetylation regulate OPRK1 gene expression in response to environmental factors such as early life stress and psychological trauma. Decreased DNA methylation in intron 2 of OPRK1, functioning as a gene enhancer, has been observed in the anterior insula of individuals with histories of childhood abuse, which correlates with altered receptor expression and stress responsivity. Postmortem samples from suicide completers with a history of severe child abuse (CA) had higher rates of KOR downregulation relative to controls and suicide completers without CA history, an effect not accompanied by alterations in multiple other genes. Hypomethylation of OPRK1 intron 2 was associated with the CA group, as low levels of DNA methylation facilitate glucocorticoid binding and subsequent regulation of OPRK1 transcription. Additionally, a specific insertion deletion (INDEL) polymorphism, rs35566036, in the OPRK1 promoter region occurred more frequently in suicide completers with major depressive disorder relative to healthy controls.
== Research == Oral nalmefene was under development for the treatment of pathological gambling, interstitial cystitis, pruritus, rheumatoid arthritis, shock, and smoking withdrawal, but development was discontinued for all of these indications. Formulations of nalmefene for use by intramuscular injection, intravenous injection, and intranasal administration are in late-stage development for the treatment of opioid-related disorders. Nalmefene might be useful to treat cocaine addiction.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.